Resources Antibody Industry Trends Week 3, Apr 2024: Bispecific ADCs

Week 3, Apr 2024: Bispecific ADCs

Biointron 2024-04-16 Read time: 2 mins
bsadcs.jpg
Image credit: DOI: 10.1016/j.apsb.2024.01.009

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently. 

Last week, a paper published in Nature demonstrated the construction of a novel BsADC targeting HER2 and HER3 with more potent therapeutic efficacy against breast cancer over monospecific ADCs. It potently inhibited the viability of MCF7, JIMT-1, BT474, BxPC-3 and SKOV-3 cancer cells in vitro.  

Meanwhile, ProfoundBio’s novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models. Set to enter clinical trials by this year, the BsADC has the potential to treat multiple tumor types and was built on the clinically validated sesutecan platform. 

Also last month, a paper described a novel T cell-redirecting anti-GPRC5D x CD3 bispecific antibody with potent antitumor activity in multiple myeloma (MM) preclinical models. Their results show that the BsADC as a monotherapy and combination therapy with immunomodulatory drugs (IMiDs) could be a highly potent and effective treatment approach for a wide population of MM patients.

Subscribe to our Antibody Industry Trends

Recent Antibody Industry Trends

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

Image credit: DOI: 10.1038/s41577-021-00542-xThe progress of COVID-19 therapies has seen remarkable strides, particularly in the development and application of antibody-based treatments. Early in the pandemic, the focus was on supportive care, but the rapid advancement in antibody therapies has sign

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.